nature portfolio

Corresponding author(s):	Zheng Guo
Last updated by author(s):	Sep 30, 2021

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

_				
ζ.	۲a	tι	c†	ICC

For	all statistical an	halyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.			
n/a	Confirmed				
	The exact	sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement			
	X A stateme	ent on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly			
	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.				
\boxtimes	A descript	tion of all covariates tested			
	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons				
\boxtimes		A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)			
	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>				
	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings				
\boxtimes	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes				
\boxtimes	Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i>), indicating how they were calculated				
Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.					
Software and code					
Poli	cy information	about <u>availability of computer code</u>			
Da	ata collection	ta collection For LSM 800 confocal, Zeiss ZEN 2.1 version was used.			
Da	ata analysis	GraphPad Prism 8 and Fiji image J.			
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.					

Data

Policy information about <u>availability of data</u>

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

Raw data associated with all figures are available in the following web site: https://doi.org/10.6084/m9.figshare.13451297 There is no restriction about data availability.

Field-spe	cific reporting				
Please select the or	ne below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.				
✓ Life sciences	Behavioural & social sciences Ecological, evolutionary & environmental sciences				
For a reference copy of t	he document with all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>				
Life scier	nces study design				
LITE SCIET	ices study design				
All studies must dis	close on these points even when the disclosure is negative.				
Sample size	No statistical methods were used to pre-determine sample sizes but our sample sizes are similar to those reported in previous publications. We clearly denoted the number of samples in the respective figures and/or figure legends.				
Data exclusions	No data were excluded from our analyses.				
Replication	At least 3 independent replicate experiments were performed. Statistical analyses were done to illustrate significance.				
Randomization	No randomization was used.				
Blinding	No blinding was done				
Reporting for specific materials, systems and methods We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response. Materials & experimental systems Nethods					
	(1)				
Antibodies used	chicken anti-GFP (Abcam, Ab13970, 1/10000 dilution), mouse anti-Pros (Developmental Studies Hybridoma Bank, AB_528440, 1/100 dilution), and Alexa 488 Fluor–conjugated secondary antibody (Thermo Fisher Scientific, dilution at 1/4000)				
Validation	The commercial anti-GFP antibody and anti-Pros antibody have been validated and published.				
Animals and other organisms					
Policy information about <u>studies involving animals; ARRIVE guidelines</u> recommended for reporting animal research					
Laboratory anima	Drosophila melanogaster femal flies were used in this study.				
Wild animals	The study did not involve wild animals.				

No formal ethical approval was required. Note that full information on the approval of the study protocol must also be provided in the manuscript.

 $\label{thm:collected} \mbox{Field-collected samples} \quad \mbox{ The study did not involve field-collected samples.}$

Ethics oversight